Close Asset Management
BIB icon

Close Asset Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Close Asset Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-160
Closed -$11K – 189
2018
Q3 		$11K Buy
160
+72
+82% +$4.71K ﹤0.01% 179
2018
Q2 		$4K Hold
88
– – ﹤0.01% 201
2018
Q1 		$4K Buy
+88
New +$5.27K ﹤0.01% 211

Other funds holding BIB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Chase Investment Counsel
Chase Investment Counsel Charlottesville, Virginia $479M AUM 81.51% 1-Year Est. Return
Virtu Financial
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
Sheaff Brock Investment Advisors
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
Capital Investment Advisors
Capital Investment Advisors Atlanta, Georgia $7.74B AUM 15.52% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

Close Asset Management's BIB Position: Q4 2018 in Review

Close Asset Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2018, closing a stake of 160 shares — an estimated $11K sold.

Close Asset Management first reported a position in BIB in Q1 2018 and held it in 3 quarters. The position peaked at $11K in Q3 2018. 27 funds tracked by Wall St. Rank hold BIB as of Q4 2018.

  • Close Asset Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Close Asset Management sold 160 ProShares Ultra NASDAQ Biotechnology shares in Q4 2018, an estimated $11K.
  • Close Asset Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2018 and held it in 3 quarters.
  • Close Asset Management's ProShares Ultra NASDAQ Biotechnology position peaked at $11K in Q3 2018.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2018.

Based on Close Asset Management's 13F filing for Q4 2018, filed 28 Jan 2019.